Aclaris Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $26.71M, a 63.23% decline year-over-year.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $72.66M, a 46.12% decline year-over-year.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $134.85M.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $103.35M.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $74.91M, a 180.43% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $26.71M, a 63.23% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $72.66M, a 69.50% decline from fiscal 2021.
- Aclaris Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $238.20M, a 2928.61% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $74.91M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $26.71M 10-K · filed 2025-02-27 | |
| 2023-06-30 | $26.71M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $72.66M 10-K · filed 2023-02-23 | |
| 2022-06-30 | $72.66M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $238.20M 10-K · filed 2023-02-23 | |
| 2021-06-30 | $134.85M 10-Q · filed 2021-11-02 | |
| 2021-03-31 | $103.35M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $7.87M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $263.00K 10-Q · filed 2021-11-02 | |
| 2017-12-31 | $19.31M 10-K · filed 2019-03-18 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | |
| 2016-06-30 | $16.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | |
| 2016-03-31 | $2.35M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $56.55M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |